Table 2 HER2 and ERα, PR expression by immunohistochemistry in paired primary breast cancers and their distant metastases
From: Receptor conversion in distant breast cancer metastases
| Â | Â | Distant metastases | |||||
|---|---|---|---|---|---|---|---|
Primary tumor | Status | - | + | Total | |||
HER2 | - | 180 (77.2%) | 6 (2.6%) | 186 | |||
| Â | + | 6 (2.6%) | 41 (17.6%) | 47 | |||
| Â | Â | 10% threshold | 1% threshold | ||||
| Â | Â | - | + | Total | - | + | total |
ERα | - | 79 (33.9%) | 7 (3.0%) | 86 | 47 (20.2%) | 12 (5.2%) | 59 |
| Â | + | 17 (7.3%) | 130 (55.8%) | 147 | 23 (9.9%) | 151 (64.8%) | 147 |
PR | - | 92 (39.5%) | 12 (5.1%) | 104 | 33 (14.2%) | 27 (11.6%) | 60 |
| Â | + | 58 (24.9%) | 71 (30.5%) | 129 | 49 (21.0%) | 124 (53.2%) | 173 |